BioMarin to Participate in the Virtual BofA Securities 2020 Napa Biopharma Conference

Rhea-AI Summary

BioMarin Pharmaceutical announced participation in the BofA Securities 2020 Napa Biopharma Conference on June 24, 2020, at 11:30 AM ET. Key representatives, Henry Fuchs, M.D., President of Worldwide Research & Development, and Brian Mueller, Acting CFO, will present. The event will feature a live audio webcast accessible via the company's investor site. BioMarin focuses on innovative therapies for serious rare disorders, with six commercialized products and numerous candidates in development.

News Market Reaction – BMRN

-0.51%

-0.51% Session move

In the trading session that priced this news, BMRN declined 0.51%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN RAFAEL, Calif., June 23, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Henry Fuchs, M.D., President, Worldwide Research & Development and Brian Mueller, Acting Chief Financial Officer, will participate in the BofA Securities 2020 Napa Biopharma Conference on June 24, 2020 at 11:30am ET.  An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.  

For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.

Contacts:
Investors	Media
Traci McCarty	Debra Charlesworth
BioMarin Pharmaceutical Inc.	BioMarin Pharmaceutical Inc.
(415) 455-7558	(415) 455-7451

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-to-participate-in-the-virtual-bofa-securities-2020-napa-biopharma-conference-301080544.html

SOURCE BioMarin Pharmaceutical Inc.

FAQ

When is BioMarin participating in the BofA Securities Napa Biopharma Conference?

BioMarin will participate in the BofA Securities Napa Biopharma Conference on June 24, 2020, at 11:30 AM ET.

Who will represent BioMarin at the BofA Securities Conference?

Henry Fuchs, M.D., President of Worldwide Research & Development, and Brian Mueller, Acting CFO, will represent BioMarin.

How can I access the live webcast of BioMarin's presentation?

The live audio webcast of BioMarin's presentation can be accessed through their investor website at https://investors.biomarin.com.

What does BioMarin specialize in?

BioMarin specializes in developing innovative therapies for serious and life-threatening rare disorders.

What is the stock symbol for BioMarin Pharmaceutical?

The stock symbol for BioMarin Pharmaceutical is BMRN.